ArticleFrontiers in public health2026
Innovations in reagent manufacturing to support the global diagnostics supply chain.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostics are not only tools for clinical decision making, but also drivers of the healthcare supply chain. They quantify and monitor the prevalence of disease across global populations. At high levels, this population health data is used to inform the purchasing and distribution of health care goods. There is overwhelming evidence that access to diagnostics is limited in low-and middle-income countries. This is true for both in-vitro molecular diagnostics and diagnostic imaging, but the scope of this work is limited to the former. While the factors contributing to limited access are numerous, interconnected, and complex, we propose a method to alleviate some restraints within the supply chain: distributed and local manufacturing of key biological reagents, or active diagnostics ingredients (ADIs). In addition to shifting the geographical boundaries of manufacturing and moving goods closer to areas of deployment, this could reduce global power imbalances by redistributing ownership of diagnostics goods, reagents, and intellectual property.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.